Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 16, 2023 09:13 ET | Source: Longeveron

Longeveron Rights Offering Declared Effective and Calendar Finalized

MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
August 14, 2023 16:05 ET | Source: Longeveron

Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs,...
August 14, 2023 08:00 ET | Source: Longeveron

Longeveron Announces Pricing for Rights Offering and Expected Calendar

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
August 11, 2023 07:30 ET | Source: Longeveron

Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update

ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer’s disease Phase 2a Trial Anticipated by October 2023 Company...
August 11, 2023 07:00 ET | Source: Longeveron

Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-B™ in the Treatment of HLHS to be held Wednesday,...
August 07, 2023 08:00 ET | Source: Longeveron

Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023

MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 20, 2023 08:00 ET | Source: Longeveron

Longeveron Appoints Lisa Locklear as Chief Financial Officer

MIAMI, July 20, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 11, 2023 08:00 ET | Source: Longeveron

Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer

MIAMI, July 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
July 10, 2023 08:00 ET | Source: Longeveron

Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors

MIAMI, July 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...
June 27, 2023 18:07 ET | Source: Longeveron

Longeveron Files Registration Statement for Rights Offering

MIAMI, June 27, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right